Headache. Other headache syndromes
Conditions
Interventions
Intervention 1: Intervention group: Ketorolac prescription 30 mgr intravenous with 30 mgr/2mL ampoules by 5 cc syringes. Intervention 2: Intervention group2: Haloperidol receivers 1 mgr intravenous wi
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: patients aged 18 to 55 who have visited the emergency room with the main complaint of headache.
Exclusion criteria
Exclusion criteria: Abnormal blood pressure(>200/100 mmhg) thunderclap (normal to the worst pain due to short time) fever acute trauma history of brain mass history of stroke history of anatomic malformation of brain Qtc>450 ms in EKG altered mental status (GCS<15) Haloperidol allergy Ketorolac allergy airway disease such as asthema active peptic ulcer advanced renal failure recent major sergury new FND any suspicious which lead to use of CT scan or LP pregnancy QT interval prolong drugs hepatic failure epilepsy or history of seizure hyperthyroidism parkinsonism chronic psychiatrics disease Concomitant use or within 2 weeks of discontinuing an MAOI inhibitor active gastritis history of GI bleeding Previous participation in the same study Previous enrollment in a study that may interfere with the current study Lack of consent to participate in the study Unwillingness to sign the consent form
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain reduction. Timepoint: 15 , 30 , 60 mintes. Method of measurement: Visual analogue scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAlireza Jalali
Tehran University of Medical Sciences
Outcome results
None listed